Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
Jean‐Claude Tardif(Montreal Heart Institute), Elvin Kedhi(Medical University of Silesia), Emmanouil S. Brilakis(Minneapolis Heart Institute Foundation), Louis Cannon(St. Mary's Medical Center), Philip J. Barter(The Heart Research Institute), Jacques Lespérance(Montreal Heart Institute), Abbey Diaz(Australian Institute of Aboriginal and Torres Strait Islander Studies), Wolfgang Köenig(German Centre for Cardiovascular Research), Normand Racine(Montreal Heart Institute), H. Klepp(Universität Ulm), Philippe L. L’Allier(Montreal Heart Institute), Ton Heestermans, C. Gessler(University of California System), Didier Carrié(Centre Hospitalier Universitaire de Toulouse), Jean-Paul Herrman(University of California System), Christie M. Ballantyne(Baylor College of Medicine), Himanshu Agarwal(Rigshospitalet), John F. Paolini(Synta Pharmaceuticals (United States)), S Eisenberg(Cerenis Therapeutics (France)), Sylvain Lanthier(Hôpital du Sacré-Cœur de Montréal), David Fortuin(Mayo Clinic Hospital), Jean Fajadet(Clinique Pasteur), Lingling Wei(University of Zurich), Céline Chayer, John J.P. Kastelein(QRx Pharma (United States)), Neil Fam(St. Michael's Hospital), G B Pelletier(Harvard University), Ahmed Tawakol(Harvard University), Jennifer Corbelli(University of Pittsburgh), Jean‐Louis Dasseux(Cerenis Therapeutics (France)), Pierre Coste, Peter Watkins(Scientific Games (Australia)), Zahi A. Fayad(Icahn School of Medicine at Mount Sinai), H. Gum(University of California System), Gilbert Gosselin(University of California System), Diego de Sousa Guerra(University of California System), Bruce W. Ennis(Cerenis Therapeutics (France)), Robbert de Winter(Institute for Atherosclerosis Research), Cindy L. Grines(University of Kentucky), Jean L. Rouleau(Montreal Heart Institute), Marie Claude Guertin(Montreal Heart Institute), Thomas Haldis(Amsterdam UMC Location University of Amsterdam), T.F. Lüscher(University Hospital Zurich), Constance Keyserling(Cerenis Therapeutics (France)), T. Huynh, Verity J. Brown(Cerenis Therapeutics (France))
Cited by 252
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)
|Radiology|2020|2.9k